STING1 and cancer: The finding that CDNs can trigger the innate immune response in eukaryotic cells through the STING signalling pathway, leading to the type I interferons (IFN) production, has prompted the extensive research and development of CDNs as potential vaccine adjuvants and agents for cancer immunotherapy [5].